Prosecution Insights
Last updated: October 02, 2026

Examiner: HAMA, JOANNE

Tech Center 4100 • Art Units: 1600 1632 1641 1642 1643 1644 1645 1646 1647 1654

This examiner grants 26% of resolved cases

Analysis

Joanne Hama is an examiner in Tech Center 4100, assigned to Art Unit 1600. With 262 resolved cases, the examiner has a well-documented history of prosecution. The allowance rate is 25.6 percent, which is notably low and indicates a challenging environment for securing a patent grant. This 25.6 percent rate suggests that the majority of applications in this docket do not reach allowance, requiring a very high standard of patentability.

The median days to allowance is 1342, reflecting a long prosecution process. This 1342-day timeline is a significant consideration for applicants in Art Unit 1600. However, the interview lift percentage is 38.2, which is a very positive sign. This 38.2 percent lift indicates that interviews are highly effective at improving the odds of an allowance, even in a difficult prosecution environment. Given the low 25.6 percent baseline allowance rate, the 38.2 percent lift suggests that direct engagement is a highly effective way to move a case toward a grant. Practitioners in Tech Center 4100 should be prepared for the 1342-day median pendency and should strongly consider using interviews to overcome the hurdles indicated by the 25.6 percent allowance rate.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

25.7%
Allow Rate
-34.3% vs TC avg
328
Total Applications
+40.0%
Interview Lift
1345
Avg Prosecution Days
Based on 265 resolved cases, 2023–2026

Rejection Statute Breakdown

7.2%
§101 Eligibility
14.6%
§102 Novelty
39.1%
§103 Obviousness
23.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18294767 METHODS TO ENHANCE EFFICACY OF COMBINED TARGETING OF IMMUNE CHECKPOINT AND MAPK PATHWAYS Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18042989 METHODS AND COMPOSITIONS FOR TREATING GLIOBLASTOMA Non-Final OA THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
18123112 CAR CELLS TARGETING AN INSERTED LIGAND Final Rejection Massachusetts Institute of Technology
18295163 COMBINATION THERAPY FOR TREATING COLORECTAL CANCER Non-Final OA Gilead Sciences, Inc.
18127284 COMPOSITIONS AND METHODS FOR PRODUCING AND USING ILCS TO TREAT HEALTH CONDITIONS Non-Final OA THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
18424004 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE GROWTH Non-Final OA Novartis AG
18322395 PURIFICATION OF ANTIBODY DRUG CONJUGATES USING A SODIUM PHOSPHATE GRADIENT Non-Final OA PFIZER INC.
18360542 COMBINATION THERAPIES FOR TREATMENT OF CANCER Non-Final OA MedImmune, LLC
18193958 METHODS OF TREATING ENHANCING BRAIN TUMORS USING COMBINATION THERAPY Non-Final OA Servier Pharmaceuticals LLC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month